viewLexagene Holdings Inc.

LexaGene reports successful results from beta testing on human urinary samples

Human clinical diagnostics is the next milestone in LexaGene’s pathogen-screening technology

test tubes
LexaGene has now completed beta tests for urinary tract infections in both dogs and humans

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) announced Thursday that a human clinical diagnostics laboratory reported successful results from beta testing using the company’s genetic analyzers.

Assurance Scientific Laboratories in Alabama said that it had processed numerous urine samples that contained pathogens and found good correlation between LexaGene’s assay and its own process.

Human clinical diagnostics is the next milestone in Massachusetts-based LexaGene’s pathogen-screening technology, which is currently being commercialized for veterinary medicine as well as agricultural industries.

READ: LexaGene develops test for deadly mosquito-borne Eastern Equine Encephalitis virus

Assurance Scientific Laboratories’ director of molecular diagnostics Dr Greer Massey said that the ability to automate extraction and sample analysis in under a minute of hands-on time will allow for lower overhead expenses for the laboratory.

“Their staff has built a very easy-to-use instrument that allows for the detection of many different targets from a single sample extraction,” said Dr Massey in a statement.

Massey also said that the lab is “looking forward” to a process that eliminates the micropipette, which is an expensive and delicate instrument used to transfer small amounts of liquids.

The laboratory’s director of microbiology Mary Beth Minyard said that LexaGene’s device “drastically reduces” hands-on time processing samples.

“Being able to combine automated sample extraction and analysis at a reasonable price would be a huge selling point for us,” Minyard said in a statement.

LexaGene has now completed beta tests for urinary tract infections in both dogs and humans, the company added. In contrast to the canine samples, human samples frequently contained multiple pathogens.

The biotechnology company’s CEO Dr Jack Regan said that he was “very pleased” that its beta program is having success. 

“We expect this trend to continue as we work through the final stages of commercializing this technology,” he told investors.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Lexagene Holdings Inc.

Price: 0.8 CAD

Market: TSX-V
Market Cap: $68.55 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexagene Holdings Inc. named herein, including the promotion by the Company of Lexagene Holdings Inc. in any Content on the Site, the Company...



Full interview: LexaGene hits milestone by having pre-commercial device in...

LexaGene (CVE: LXG- OTCQB: LXXGF) CEO Dr Jack Regan joined Steve Darling from Proactive Vancouver with news the company now has one of their devices that tests for COVID-19 and other respiratory pathogens being used at the Dartmouth-Hitchcock Medical Center in Hanover, New Hampshire. Regan...

6 days, 7 hours ago

2 min read